Mounjaro is a medication used for the treatment of type 2 diabetes, which also results in significant weight loss.
Mounjaro
Mounjaro is an emerging tirzepatide prescription medication for the treatment of type 2 diabetes. It has also resulted in significant weight loss offering a new approach to shedding unwanted pounds. Mounjaro works to suppress your appetite and is typically prescribed to individuals struggling with obesity who have not found success with diet and exercise alone.
Mounjaro helps regulate your appetite and mood. The GLP-1 appetite suppressant stimulates the release of insulin and glucagon to promote fullness and decrease food intake and cravings.
Reduced hunger pangs and improved satiety are the key mechanisms through which this medication aids in weight loss. It yields optimal results when combined with a proper diet and exercise.
Taking Mounjaro as prescribed by your healthcare provider is crucial for its effectiveness and safety. Typically, Mounjaro is taken once a week. Your doctor will determine the appropriate dosage based on your individual needs and response to the medication. It is essential to follow their instructions closely and not adjust the dose on your own.
Weight loss results on Mounjaro can vary significantly from person to person. On average, individuals may experience a gradual weight loss of around 5-10% of their initial body weight over several months when combined with a reduced-calorie diet and increased physical activity.
The exact amount of weight you lose will depend on various factors, including your starting weight, adherence to the prescribed regimen, and individual metabolism.
Mounjaro is only FDA-approved as a type 2 diabetes treatment, but the FDA is expected to review and approve the drug for weight loss in late 2023. Clinical trials and research are ongoing to assess its safety and efficacy. It’s essential to consult with your healthcare provider for the most up-to-date information on Mounjaro’s FDA status.
Like many prescription medications, Mounjaro may come with potential side effects. Most common side effects may include nausea, diarrhea, constipation, stomach pain, indigestion, vomiting, and decreased appetite. These effects tend to be mild and often diminish over time.
However, it’s essential to be aware of less common, but more severe side effects, such as inflammation of the pancreas (pancreatitis), low blood sugar (hypoglycemia), kidney problems (kidney failure), serious allergic reactions, severe stomach problems, changes in vision, and gallbladder problems. If you experience any unusual or severe symptoms while taking Mounjaro, contact your healthcare provider immediately.
WARNING: RISK OF THYROID C-CELL TUMORS. Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
You can find the packaging insert here https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf